Respiratory Syncytial Virus (RSV)

Infectious Diseases
5
Pipeline Programs
5
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
250%
Small Molecule
125%
Monoclonal Antibody
125%
+ 2 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

MAXVAX Biotechnology
MAXVAX BiotechnologyChina - Chengdu
2 programs
1
1
Recombinant Respiratory Syncytial Virus VaccinePhase 3Vaccine1 trial
Recombinant Respiratory Syncytial Virus VaccinePhase 1/2Vaccine1 trial
Active Trials
NCT06642558Active Not RecruitingEst. Feb 2027
NCT07272434RecruitingEst. Dec 2028
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
PalivizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT02968173Completed50Est. Jul 2017
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
PresatovirPhase 2Small Molecule1 trial
Active Trials
NCT02534350Completed61Est. Sep 2017
Vaxart
VaxartSOUTH SAN FRANCISCO, CA
1 program
1
VXA-RSV-f TabletsPhase 11 trial
Active Trials
NCT02830932CompletedEst. Sep 2017
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Palivizumab 15 mg/kgN/A1 trial
Active Trials
NCT06851806Not Yet Recruiting138Est. Feb 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
MAXVAX BiotechnologyRecombinant Respiratory Syncytial Virus Vaccine
AbbViePalivizumab
Gilead SciencesPresatovir
MAXVAX BiotechnologyRecombinant Respiratory Syncytial Virus Vaccine
VaxartVXA-RSV-f Tablets
AstraZenecaPalivizumab 15 mg/kg

Clinical Trials (6)

Total enrollment: 249 patients across 6 trials

NCT07272434MAXVAX BiotechnologyRecombinant Respiratory Syncytial Virus Vaccine

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

Start: Oct 2025Est. completion: Dec 2028
Phase 3Recruiting
NCT02968173AbbViePalivizumab

A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus

Start: Nov 2016Est. completion: Jul 201750 patients
Phase 3Completed
NCT02534350Gilead SciencesPresatovir

Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection

Start: Dec 2015Est. completion: Sep 201761 patients
Phase 2Completed
NCT06642558MAXVAX BiotechnologyRecombinant Respiratory Syncytial Virus Vaccine

Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above

Start: Nov 2024Est. completion: Feb 2027
Phase 1/2Active Not Recruiting
NCT02830932VaxartVXA-RSV-f Tablets

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Start: Jun 2016Est. completion: Sep 2017
Phase 1Completed
NCT06851806AstraZenecaPalivizumab 15 mg/kg

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

Start: Nov 2025Est. completion: Feb 2027138 patients
N/ANot Yet Recruiting

Related Jobs in Infectious Diseases

Senior Recruiter

Invivyd
New Haven, CT (Northeast preferred)
5h ago
$120K - $160K/yr

Senior Associate Scientist (contract), Upstream Polysaccharide Process Development

VaxCyte
San Carlos, California, United States
8h ago
$56/hr

Senior Associate Scientist (contract), Polysaccharide Analytical Development

VaxCyte
San Carlos, California, United States
8h ago
$56/hr

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
12h ago
$179K - $237K/yr

First Line Sales Leader (Medan)

GSK
Indonesia - Sumatera Utara
Yesterday

General Worker

GSK
Pakistan - Sindh - Karachi
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 249 patients
5 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)